Asia Pacific pharmaceutical CDMO market will grow by 8.3% annually with a total addressable market cap of $725.2 billion over 2020-2030 owing to the rising demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.
Highlighted with 44 tables and 53 figures, this 136-page report “Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on a comprehensive research of the entire Asia Pacific pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.
Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical Industry
• Biopharmaceutical Industry
Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical Contract Manufacturing Organization (CMO)
• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging
Pharmaceutical Contract Research Organization (CRO)
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services
Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Asia Pacific Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 34
2.5 Porter’s Fiver Forces Analysis 38
3 Segmentation of Asia Pacific Market by Category 42
3.1 Market Overview by Category 42
3.2 Pharmaceutical Industry 44
3.3 Biopharmaceutical Industry 45
4 Segmentation of Asia Pacific Market by Service Type 46
4.1 Market Overview by Service Type 46
4.2 Pharmaceutical Contract Manufacturing Organization (CMO) 48
4.2.1 Active Pharmaceutical Ingredients (API) 49
4.2.2 Finished Dosage Formulations (FDF) 50
4.2.3 Secondary Packaging 52
4.3 Pharmaceutical Contract Research Organization (CRO) 53
4.3.1 CRO for Pre-clinical Development 55
4.3.2 CRO for Phase I Trials 56
4.3.3 CRO for Phase II Trials 57
4.3.4 CRO for Phase III Trials 58
4.3.5 CRO for Phase IV Trials 59
4.3.6 Laboratory Services 60
4.3.7 Consulting Services 61
4.3.8 Data Management Services 62
5 Segmentation of Asia Pacific Market by Therapeutic Application 63
5.1 Market Overview by Therapeutic Application 63
5.2 Infectious Diseases 65
5.3 Oncology 66
5.4 Metabolic Disorders 67
5.5 Cardiovascular Disorders 68
5.6 Central Nervous System 69
5.7 Pulmonary Disorders 70
5.8 Gastrointestinal Disorders 71
5.9 Other Therapeutic Applications 72
6 Segmentation of Asia Pacific Market by End User 73
6.1 Market Overview by End User 73
6.2 Pharmaceutical & Biopharmaceutical Companies 75
6.3 Medical Device Companies 76
6.4 Academic Institutes 77
7 Asia-Pacific Market 2019-2030 by Country 78
7.1 Overview of Asia-Pacific Market 78
7.2 Japan 81
7.3 China 84
7.4 Australia 86
7.5 India 88
7.6 South Korea 90
7.7 Rest of APAC Region 92
8 Competitive Landscape 94
8.1 Overview of Key Vendors 94
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
8.3.1 Company Profiles of CMO 99
Aenova Group 99
Baxter BioPharma Solutions 101
Boehringer Ingelheim 102
Catalent Inc. 103
Famar S.A. 104
Hospira, Inc. 105
Jubilant Life Sciences Ltd. 106
Lonza Group 107
Patheon Inc. 108
Pfizer CentreSource 109
Recipharm AB 110
Vetter Pharma International GmbH 111
8.3.2 Company Profiles of CRO 113
Charles River Laboratories 113
CMIC Co. Ltd 115
Covance Inc. 116
Hangzhou Tigermed Consulting Co Ltd 117
ICON Plc 118
IQVIA Holdings Inc. 119
LSK Asia Pacific Pharma Service Co Ltd 120
Novotech Pty Ltd 121
PAREXEL International Corporation 122
Pharmaceutical Product Development LLC (PPD) 123
PRA Health Sciences Inc. 124
Quanticate Ltd 125
Samsung Bioepis Co. Ltd 126
SGS SA (SGS Life Sciences) 127
Syneos Health Inc. 128
WuXi AppTec Inc. 129
9 Investing in Asia Pacific Market: Risk Assessment and Management 130
9.1 Risk Evaluation of Asia Pacific Market 130
9.2 Critical Success Factors (CSFs) 133
Related Reports and Products 136
Table 1. Snapshot of Asia Pacific Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030 18
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 28
Table 4. Worldwide Total Number of Registered Clinical Trials 30
Table 5. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical CDMO Market 34
Table 6. Asia Pacific Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 42
Table 7. Asia Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 46
Table 8. Asia Pacific Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn 48
Table 9. Asia Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn 49
Table 10. Asia Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn 51
Table 11. Asia Pacific Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn 54
Table 12. Asia Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 63
Table 13. Asia Pacific Pharmaceutical CDMO Market by End User, 2019-2030, $ bn 73
Table 14. APAC Pharmaceutical CDMO Market by Country, 2019-2030, $ bn 79
Table 15. Japan Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 83
Table 16. Japan Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 83
Table 17. Japan Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 83
Table 18. China Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 85
Table 19. China Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 85
Table 20. China Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 85
Table 21. Australia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 87
Table 22. Australia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 87
Table 23. Australia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 87
Table 24. India Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 89
Table 25. India Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 89
Table 26. India Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 89
Table 27. South Korea Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 91
Table 28. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 91
Table 29. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 91
Table 30. Pharmaceutical CDMO Market in Rest of APAC by Country, 2019-2030, $ bn 93
Table 31. Breakdown of World CMO Market by Key Vendor, 2019, % 96
Table 32. Breakdown of World CRO Market by Key Vendor, 2019, % 96
Table 33. Aenova Group: Company Snapshot 99
Table 34. Aenova Group: Business Segmentation 99
Table 35. Aenova Group: Product Portfolio 100
Table 36. Aenova Group: Revenue, 2016-2018, $ bn 100
Table 37. Aenova Group: Recent Developments 100
Table 38. Charles River Laboratories: Company Snapshot 113
Table 39. Charles River Laboratories: Business Segmentation 113
Table 40. Charles River Laboratories: Product Portfolio 114
Table 41. Charles River Laboratories: Revenue, 2016-2018, $ bn 114
Table 42. Charles River Laboratories: Recent Developments 114
Table 43. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 131
Table 44. Critical Success Factors and Key Takeaways 134
